Lyra Therapeutics Inc (LYRA)

Mar 13, 2025, 4:01 PM EDT - 5 weeks ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 4:01 PM EST - 5 months ago

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 15, 2024, 7:00 AM EDT - 6 months ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Sep 27, 2024, 7:00 AM EDT - 7 months ago

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

Aug 14, 2024, 4:01 PM EDT - 8 months ago

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 21, 2024, 9:14 AM EDT - 11 months ago

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

May 6, 2024, 7:59 AM EDT - 1 year ago

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

Apr 30, 2024, 4:04 PM EDT - 1 year ago

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 28, 2024, 4:39 AM EDT - 1 year ago

3 'Buy-Rated' Biotech Stocks Under $10

ADMA GERN

Apr 26, 2024, 4:51 PM EDT - 1 year ago

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 1, 2024, 4:01 PM EST - 1 year ago

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2023, 4:01 PM EST - 1 year ago

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:00 AM EST - 1 year ago

Lyra Therapeutics to Participate in Upcoming Investor Conferences

Oct 16, 2023, 7:00 AM EDT - 1 year ago

Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer

Oct 10, 2023, 10:56 AM EDT - 1 year ago

Lyra Therapeutics: Hold For Phase 3 Topline

Oct 9, 2023, 1:20 AM EDT - 1 year ago

Lyra Therapeutics' Nasal Matrix In Focus: Sniffing Out Opportunity

Sep 12, 2023, 7:00 AM EDT - 1 year ago

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Aug 29, 2023, 7:00 AM EDT - 1 year ago

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

Aug 8, 2023, 4:01 PM EDT - 1 year ago

Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jul 13, 2023, 7:30 AM EDT - 1 year ago

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

Jun 26, 2023, 8:00 AM EDT - 1 year ago

Lyra Therapeutics: Bob Langer-Founded Company Shows Promising Data For Sinus Treatment

Jun 2, 2023, 7:30 AM EDT - 2 years ago

Lyra Therapeutics to Present at Jefferies Healthcare Conference

Jun 1, 2023, 7:29 AM EDT - 2 years ago

Lyra Therapeutics Announces Closing of $50.0 Million Private Placement

May 26, 2023, 7:57 AM EDT - 2 years ago

Lyra Therapeutics Announces $50.0 Million Private Placement

May 12, 2023, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 4:01 PM EDT - 2 years ago

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

Apr 25, 2023, 7:59 AM EDT - 2 years ago

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

Apr 5, 2023, 9:04 AM EDT - 2 years ago

Lyra Therapeutics: Negative EV With A Very Compelling Treatment For Chronic Rhinosinusitis In Phase 3

Mar 29, 2023, 4:06 PM EDT - 2 years ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 27, 2023, 7:59 AM EST - 2 years ago

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

Feb 6, 2023, 7:56 AM EST - 2 years ago

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Nov 8, 2022, 4:01 PM EST - 2 years ago

Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 13, 2022, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study

Sep 10, 2022, 8:00 AM EDT - 2 years ago

LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting

Sep 8, 2022, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients

Sep 6, 2022, 7:00 AM EDT - 2 years ago

Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022

Aug 29, 2022, 7:00 AM EDT - 2 years ago

Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR‑210 in Two Oral Presentations at ARS Annual Meeting

Aug 9, 2022, 7:00 AM EDT - 2 years ago

Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 5, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022

Jul 5, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer

May 26, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics to Present at Upcoming Investor Conferences

May 18, 2022, 12:46 PM EDT - 3 years ago

Lyra Therapeutics: Progress In The Clinic

May 10, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Apr 29, 2022, 9:07 AM EDT - 3 years ago

Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022

Apr 25, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

Apr 21, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022

Apr 13, 2022, 7:00 AM EDT - 3 years ago

Lyra Therapeutics Announces Closing of $100.5 Million Private Placement

Apr 8, 2022, 12:11 PM EDT - 3 years ago

Lyra Therapeutics Stock Surges On Equity Raise Of $100M

Apr 8, 2022, 7:34 AM EDT - 3 years ago

Lyra Therapeutics Announces $100.5 Million Private Placement